Immune-mediated toxicities associated with antibody therapy of cancer
| Antibody regimen . | Target antigen . | Cancer type . | Toxicities . | Reference(s) . |
|---|---|---|---|---|
| Ipilimumab | CTLA-4 | Hodgkin disease, myeloma, AML, CML, CLL, NHL | Arthritis, hyperthyroidism, pneumonitis | 29 |
| Ipilimumab | CTLA-4 | Melanoma | Colitis, bowel perforation, vitiligo, hypophysitis | 33 |
| Tremelimumab or ipilimumab | CTLA-4 | Melanoma | Colitis, dermatitis | 30,32,95 |
| Anti-CTLA-4 + TAA peptides | CTLA-4 | Melanoma | Colic, dermatitis, uveitis, enterocolitis, hepatitis, hypophysitis, vitiligo, pulmonary leukocyte infiltration | 28,96,,–99 |
| Anti-CTLA-4 (with vaccines and cytokines) | CTLA-4 | Melanoma (mouse and human) | Melanocyte destruction, enteritis | 31,100,–102 |
| Anti-CTLA-4, irradiated tumor cells, GM-CSF | CTLA-4 | C2 prostate cancer (mouse) | Prostatitis, destruction of prostate epithelium | 103 |
| MDX-1106 | PD-1 | Melanoma, RCC, NSCLC, prostate | Colitis | 34 |
| Alemtuzumab | CD52 | CLL | Destruction of normal leukocytes, leading to susceptibility to infections | 42,44,104 |
| Gemtuzumab | CD33 | AML | Infection, sepsis, pneumonia | 36,–38 |
| Rituxumab | CD20 | Lymphoma | Suppression of B cells leading to deficiency in immunoglobulin and infections | 48,49,105,106 |
| Antibody regimen . | Target antigen . | Cancer type . | Toxicities . | Reference(s) . |
|---|---|---|---|---|
| Ipilimumab | CTLA-4 | Hodgkin disease, myeloma, AML, CML, CLL, NHL | Arthritis, hyperthyroidism, pneumonitis | 29 |
| Ipilimumab | CTLA-4 | Melanoma | Colitis, bowel perforation, vitiligo, hypophysitis | 33 |
| Tremelimumab or ipilimumab | CTLA-4 | Melanoma | Colitis, dermatitis | 30,32,95 |
| Anti-CTLA-4 + TAA peptides | CTLA-4 | Melanoma | Colic, dermatitis, uveitis, enterocolitis, hepatitis, hypophysitis, vitiligo, pulmonary leukocyte infiltration | 28,96,,–99 |
| Anti-CTLA-4 (with vaccines and cytokines) | CTLA-4 | Melanoma (mouse and human) | Melanocyte destruction, enteritis | 31,100,–102 |
| Anti-CTLA-4, irradiated tumor cells, GM-CSF | CTLA-4 | C2 prostate cancer (mouse) | Prostatitis, destruction of prostate epithelium | 103 |
| MDX-1106 | PD-1 | Melanoma, RCC, NSCLC, prostate | Colitis | 34 |
| Alemtuzumab | CD52 | CLL | Destruction of normal leukocytes, leading to susceptibility to infections | 42,44,104 |
| Gemtuzumab | CD33 | AML | Infection, sepsis, pneumonia | 36,–38 |
| Rituxumab | CD20 | Lymphoma | Suppression of B cells leading to deficiency in immunoglobulin and infections | 48,49,105,106 |
CTLA-4 indicates cytotoxic T lymphocyte antigen-4; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; and NSCLC, non–small cell lung cancer.